Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.
Actively Recruiting
Researchers are studying the long-term effects of aleniglipron, taken once daily, in adults with obesity or overweight who also have weight-related health problems. This Phase 3 global, randomized, placebo-controlled, and double-blind trial aims to evaluate how well aleniglipron works, how safe it is, and how well patients tolerate it over at least 76 weeks. The study also compares aleniglipron with placebo in terms of body weight changes, blood pressure, lipid levels, and patient-reported outcomes. Participants will be randomly assigned to receive one of three doses of aleniglipron or a placebo, all taken orally once daily. Along with the medication, all participants will follow a reduced-calorie diet and increase physical activity. The treatment phase lasts at least 76 weeks, during which effects on weight and other health measures will be assessed. During the study, participants will undergo assessments of body weight, waist size, blood pressure, cholesterol, blood sugar, and quality of life measures from the start through week 76. Researchers will monitor safety and tolerability throughout the treatment period. This long-term study will help understand the impact of aleniglipron on weight management and related health factors over more than a year of treatment.
Actively Recruiting
Researchers are evaluating and comparing two treatments for patients with treatment-resistant depression TRD intravenous racemic ketamine and intranasal Esketamine Spravato4. This study aims to assess how effective each treatment is at reducing depression symptoms, how acceptable they are to patients, and how well patients tolerate any side effects. The study also explores factors that might predict which treatment works better for certain individuals. It is a randomized, multi-site, phase 3 comparative effectiveness trial enrolling about 400 adult participants. Participants will be randomly assigned to receive either racemic ketamine or Esketamine Spravato. Racemic ketamine will be administered intravenously over 40 minutes with a maximum dose of 60 mg per day and a lifetime limit of 8 doses. Esketamine will be given as a nasal spray with doses ranging from 56 to 84 mg, with allowances to reduce to 28 mg if needed for tolerance. The treatment period spans 4 weeks with dosing sessions following FDA guidelines. Throughout the study, participants will be monitored regularly for changes in their depression symptoms using self-reported and clinician assessments. Researchers will evaluate response, remission, suicidal ideation, disability level, quality of life, healthcare use, acceptability, global severity, improvement, tolerability, and safety over the treatment period. The primary outcome is self-reported effectiveness at 30 days. Participants will be followed for the duration of the trial, which lasts up to 5 years in total.
Actively Recruiting
This observational study follows patients with treatment-resistant depression who are starting or continuing treatment with either intravenous IV ketamine or intranasal esketamine Spravato. It aims to compare these two approaches by collecting information on patient satisfaction, usage patterns, long-term effectiveness, and safety over a five-year period. The study will enroll 450 patients across six sites, including academic medical centers and community psychiatric practices. Participants receive either IV ketamine or Spravato as prescribed by their clinicians for moderate to severe treatment-resistant depression without psychotic features. Patients newly starting treatment or continuing treatment within 75 days are eligible. The study observes these treatments in routine clinical use without assigning specific interventions. During the study, participants provide data and assessments at regular intervals up to six months, including treatment satisfaction using the TSQM-9 questionnaire, depression severity reported by patients and clinicians, treatment patterns such as number of sessions and dosage, reasons for stopping treatment, and monitoring of adverse events. The study continues to observe participants for up to five years to gather long-term follow-up information on safety and effectiveness.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.